Lupin Limited received US FDA approval for generic Famotidine Injection, expanding its injectable portfolio in the American healthcare market.
Global pharmaceutical company Lupin Limited has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL), Single-Dose Vials. This approval signifies a significant step for Lupin, allowing it to market a generic equivalent of Pepcid® Injection, 10 mg/mL, originally developed by Merck Sharp & Dohme Corp… The new product will be manufactured at Lupin's facility in Nagpur, India.
Famotidine is a well-established histamine-2 (H2) receptor antagonist that works by reducing gastric acid secretion, making it effective in treating various gastrointestinal conditions. The approved injection is indicated for intravenous use in hospitalized adult patients suffering from pathological hypersecretory conditions or intractable ulcers. It also serves as a short-term alternative to oral medication for patients unable to take oral forms, treating conditions such as active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD). Furthermore, it is approved for maintenance therapy in duodenal ulcer patients after healing and for the treatment of pathological hypersecretory conditions like Zollinger-Ellison Syndrome. The patents on famotidine expired in 2001, paving the way for generic versions like Lupin's offering.
From an economic and industry perspective, this FDA approval is a strategic win for Lupin. It strengthens the company's presence in the U.S. institutional market and is a key part of its strategy to expand its portfolio of complex generics and injectable products in North America. The introduction of Famotidine Injection is expected to diversify Lupin's product mix, shifting it towards higher-margin injectable products from traditional oral solids. This move is crucial for providing a stable, multi-million dollar annual revenue stream and offering protection against the aggressive price erosion often seen in the oral generic markets. Lupin's continued focus on complex generics is considered vital for its long-term margin expansion goals.
The estimated annual sales for Famotidine Injection in the U.S. market are reported to be approximately USD 8.7 million according to IQVIA MAT March 2026 data, while another source indicates a market opportunity of USD 16.3 million for the same period. Despite the positive regulatory news and strong financial results for Q4 FY26, which saw Lupin's net profit nearly double and revenue jump significantly, the company's stock experienced a slight dip. This market reaction suggests that investors are looking beyond immediate gains, focusing on broader factors such as the company's valuation, competitive landscape, and long-term sector outlook. While the immediate revenue impact of this specific approval may be modest relative to Lupin's overall turnover, it underscores the company's consistent execution in ANDA filings and its ability to navigate the complex U.S. regulatory environment, which remains a significant competitive advantage.
